###begin article-title 0
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models
###end article-title 0
###begin p 1
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 504 507 504 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 517 520 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 549 552 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
Cyclin D1 is one of the most commonly overexpressed oncogenes in breast cancer, with 45-50% of primary ductal carcinomas overexpressing this oncoprotein. Targeted deletion of the gene encoding cyclin D1 demonstrates an essential role in normal mammary gland development while transgenic studies provide evidence that cyclin D1 is a weak oncogene in mammary epithelium. In a recent exciting development, Yu et al. demonstrate that cyclin D1-deficient mice are resistant to mammary carcinomas induced by c-neu and v-Ha-ras, but not those induced by c-myc or Wnt-1. These findings define a pivotal role for cyclin D1 in a subset of mammary cancers in mice and imply a functional role for cyclin D1 overexpression in human breast cancer.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Breast cancer is a heterogeneous disease arising from multiple genetic changes in oncogenes and tumour suppressor genes with pivotal roles in the homeostatic control of mammary epithelial cell proliferation, differentiation and death. Aberrations in the expression and function of these genes lead to clonal expansion with subsequent acquisition of invasive and metastatic phenotypes.
###end p 3
###begin p 4
###xml 457 462 <span type="species:ncbi:10090">mouse</span>
An increasing number of genes have been implicated in the evolution of breast cancer, and this list is expected to expand with the development of new genomics tools. Studies to date have relied on correlations between gene mutation, gene expression and breast cancer phenotype to identify candidate genes, with demonstration of function dependent on mechanistic studies in diverse experimental systems. One powerful model system is the genetically modified mouse where several genes induce mammary carcinoma when expressed alone or in combination.
###end p 4
###begin p 5
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 357 360 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 614 619 <span type="species:ncbi:9606">human</span>
In a major recent advance, the laboratory of Piotr Sicinski has combined transgenic and targeted gene deletion approaches to address the requirement for the cell cycle oncoprotein, cyclin D1, in the induction of mammary carcinoma [1]. These novel data demonstrate that cyclin D1 is essential for the development of mammary cancers induced by c-neu and v-Ha-ras, but not those induced by c-myc or Wnt-1. This is the first genetic evidence of an absolute requirement for cyclin D1 in the formation of a subset of mammary cancers, and supports an expanding literature implicating this oncoprotein in the evolution of human breast cancer.
###end p 5
###begin p 6
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 318 319 318 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 593 594 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 198 203 <span type="species:ncbi:9606">human</span>
Cyclin D1 is the product of the CCND1 gene and was first implicated in tumourigenesis following localisation to chromosome 11q13 [2], a region of the genome that is commonly amplified in a range of human carcinomas including breast cancer [3]. Cyclin D1 plays a pivotal role in the regulation of progression from the G1 to the S phase of the cell cycle through the formation of active enzyme complexes with cyclin-dependent kinases Cdk4 and Cdk6. These kinases phosphorylate substrates including the retinoblastoma gene product, pRb, thus relieving pRb's inhibitory function on S phase entry [4]. This rate-limiting step in cell cycle progression is regulated by a number of mechanisms including cyclin D1 abundance [4]; consequently, dysregulation of cyclin D1 gene expression or function is a probable contributor to loss of normal cell cycle control during carcinogenesis.
###end p 6
###begin title 7
Cyclin D1 in breast cancer
###end title 7
###begin p 8
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Chromosome 11q13 is amplified in ~15% of primary breast cancers, and cyclin D1 is currently the most probable candidate oncogene at this locus [3]. The early demonstration that cyclin D1 mRNA was overexpressed in ~45% of breast carcinomas identified cyclin D1 as one of the most frequently overexpressed oncogenes in primary breast cancer [5], an observation subsequently confirmed by immunohistochemical studies [6,7].
###end p 8
###begin p 9
###xml 116 123 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In situ</italic>
###xml 214 221 214 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
There has been some debate as to when cyclin D1 overexpression is first observed in the evolution of breast cancer. In situ hybridisation studies suggest that cyclin D1 overexpression occurs at the transition from in situ to invasive cancer [8], while immunohistochemical studies of preneoplastic lesions demonstrate that overexpression was already apparent in hyperplasia and increased with increasing malignancy [9]. If substantiated by further studies, the latter data are compatible with a potential role for cyclin D1 in the early phases of breast cancer development.
###end p 9
###begin p 10
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Studies on primary breast cancers indicate that overexpression is confined to specific phenotypes, implying different roles in different subtypes of the disease. Lobular carcinoma appears to universally overexpress cyclin D1 [10], while overexpression in ductal carcinoma is confined almost exclusively to oestrogen receptor positive cases [5]. A potential functional link between oestrogen receptor positivity and cyclin D1 overexpression is supported by evidence that cyclin D1 plays a major role in oestrogen-induced mitogenesis in breast cancer cells [11].
###end p 10
###begin title 11
Cyclin D1 in mammary gland development and carcinogenesis
###end title 11
###begin p 12
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Mammary development is impaired in cyclin D1 null mice such that, although the basic ductal structure forms normally at puberty, alveoli do not develop during pregnancy and lactation does not occur [12,13]. This defect does not appear to reflect a necessity for cyclin D1 per se, since epithelium lacking both cyclin D1 and p27 can form a normal mammary gland [14], as can epithelium in which cyclin D1 has been replaced by cyclin E [15]. Instead, it appears that the specific requirement is for timely epithelial cell proliferation.
###end p 12
###begin p 13
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 853 856 853 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 862 865 862 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 961 964 961 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 977 980 977 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 190 194 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 373 377 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 956 960 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 969 973 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Overexpression of cyclin D1 in the virgin mammary gland causes increased proliferation and precocious alveolar development, mimicking early pregnancy [16]. These mouse mammary tumour virus (MMTV)-cyclin D1 mice eventually develop mammary adenocarcinomas, with a mean age at onset of ~18 months [16]. This is a considerably longer timeframe than those observed for MMTV-myc mice (~11 months), MMTV-Ha-ras mice (~5.6 months) or MMTV-neu (~3 months) mice [17,18]. While the oncogenic capacity of these genes in mammary tissue is clear, the long latencies of c-myc-induced and cyclin D1-induced tumours in particular indicate that, on their own, they are weak oncogenes and may require cooperating oncogenes for efficient carcinogenesis. Indeed, almost one-half of the tumours induced by tetracycline-regulated c-Myc expression also acquired mutations in K-ras or N-ras[19], complementing early data demonstrating that tumour incidence in the presence of both MMTV-myc and MMTV-Ha-ras was accelerated compared with either oncogenealone [18].
###end p 13
###begin title 14
Cooperation between oncogenes in mammary carcinogenesis
###end title 14
###begin p 15
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 271 274 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 869 872 869 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 890 893 890 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1059 1060 1059 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1294 1297 1294 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 1315 1318 1315 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 1355 1360 1355 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 1378 1381 1378 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 1432 1433 1432 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 864 868 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 885 889 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 959 963 <span type="species:ncbi:10090">mice</span>
###xml 1289 1293 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1310 1314 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1350 1354 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1373 1377 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
The data outlined above focus attention on a critical question: are there preferred pathways that cooperate with cyclin D1 to promote mammary carcinogenesis? The publication of Yu et al.[1] addresses this issue and, importantly, indicates preferential cooperation with c-neu and v-Ha-ras. These experiments provide further strong evidence for a critical role for cyclin D1 in the development of mammary cancer, but also raise additional questions about the interaction between different oncogenes in a cell-specific context. What is clearly apparent, and may have been inferred from early studies in cyclin D1 null mice, is that cyclin D1 plays a very specific role in the normal mammary gland and mammary carcinogenesis. The defect in mammary development in cyclin D1 null mice occurs despite the presence of the often redundant D2 and D3 cyclins [1]. Similarly, MMTV-neu-induced and MMTV-ras-induced tumourigenesis was not impaired in cyclin D2 and D3 null mice, and cyclin E could substitute for cyclin D1 in tumourigenesis as well as mammary development [1]. This implies it is the tissue-specific regulation and timing of cyclin D1 expression that is critical to these processes. In support of this concept, increased expression of cyclin D1 but not cyclins D2 and D3 was observed in MMTV-neu-induced and MMTV-ras-induced mammary tumours, while MMTV-Wnt-1-induced and MMTV-myc-induced tumours expressed both cyclins D1 and D2 [1].
###end p 15
###begin p 16
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 404 408 404 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Kip1</sup>
###xml 502 507 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 618 621 618 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
The lack of dependence of c-myc-induced tumours of the mammary gland on cyclin D1 is perhaps not surprising given evidence that these two oncogenes act through separate pathways to activate cyclin E-Cdk2 and cell cycle progression in breast cancer cells [20]. Evidence from other model systems that cyclin D2 is a Myc-induced gene that contributes to cyclin E-Cdk2 activation through sequestration of p27Kip1 into cyclin D2-cyclin-dependent kinase complexes similarly supports the data presented by Yu et al. It is noteworthy, however, that in the lymphoid system there is strong cooperativity between cyclin D1 and c-myc in lymphomagenesis [21], again illustrating the cell specificity of oncogene interactions in tumourigenesis.
###end p 16
###begin p 17
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 324 327 324 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt</italic>
###xml 512 514 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 595 597 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 636 641 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
The Wnt-1 oncogene has major effects on mammary gland development and is a potent oncogene in mammary epithelium. Wnt-1 induced precocious mammary gland development in cyclin D1 null mice, indicating that it could replace cyclin D1 function in both development and tumourigenesis [1]. Such data do not support the view that Wnt signalling through accumulation of beta-catenin and, consequently, increased cyclin D1 gene expression is a major pathway in mammary epithelium, as has been proposed in other tissues [22]. While this pathway is probably intact in the mammary gland and breast cancer [23], the present data support a role for Wnt-1 induction of cyclin D2 as a significant downstream effector in mammary epithelium.
###end p 17
###begin title 18
Conclusions
###end title 18
###begin p 19
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 435 438 435 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt-1</italic>
###xml 155 160 <span type="species:ncbi:10090">mouse</span>
Taken together, these data provide compelling evidence for a requirement for appropriate regulation of cyclin D1 gene expression in the development of the mouse mammary gland and the induction of tumours by c-neu and v-Ha-ras. This appears to relate to the temporal expression of the gene rather than its function since a cyclin E knockin at the cyclin D1 locus can restore normal function. In light of the induction of cyclin D2 by c-myc and Wnt-1, it might be expected that a cyclin D2 knockin would produce a similar phenotype.
###end p 19
###begin p 20
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 467 470 467 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">erb</italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 579 582 579 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">erb</italic>
###xml 1159 1167 <span type="species:ncbi:9606">patients</span>
Finally, Yu et al. suggest that their data provide strong evidence for targeting cyclin D1 for potential therapeutic intervention in breast cancer, particularly those with activated Neu-Ras pathways [1]. While their data are not incompatible with such a conclusion, there are a number of factors that suggest this is unlikely to be a priority area in the immediate future. Several drugs are currently in advanced preclinical and clinical development targetting the c-erbB-2 receptor, its tyrosine kinase domain [24] and several downstream signalling targets [25]. Furthermore, c-erbB-2 overexpressing tumours, being predominantly oestrogen receptor negative, are unlikely to overexpress cyclin D1. If cyclin D1 overexpression is an early initiating event in the development of breast cancer, however, novel therapeutic strategies that inhibit its aberrant expression or function may well have a role in the ultimate prevention of a significant proportion of breast cancers. Only time and further insightful experiments into the control of cyclin D1 expression and function in mammary epithelium, as reported by Sicinski and colleagues, will determine whether patients will ultimately benefit from these important biological advances.
###end p 20
###begin title 21
Abbreviations
###end title 21
###begin p 22
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
MMTV = mouse mammary tumour virus.
###end p 22
###begin title 23
Acknowledgements
###end title 23
###begin p 24
This work was supported in part by grants from the National Health and Medical Research Council of Australia, The Cancer Council New South Wales, and the US Army Medical Research and Materiel Command (DAMD17-99-9184 and DAMD17-00-1-0252).
###end p 24
###begin article-title 25
Specific protection against breast cancers by cyclin D1 ablation.
###end article-title 25
###begin article-title 26
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcl1</italic>
A novel cyclin encoded by a bcl1-linked candidate oncogene.
###end article-title 26
###begin article-title 27
###xml 34 39 <span type="species:ncbi:9606">human</span>
Chromosome 11q13 abnormalities in human breast cancer.
###end article-title 27
###begin article-title 28
Cancer cell cycles.
###end article-title 28
###begin article-title 29
###xml 48 53 <span type="species:ncbi:9606">human</span>
Expression and amplification of cyclin genes in human breast cancer.
###end article-title 29
###begin article-title 30
###xml 45 50 <span type="species:ncbi:9606">human</span>
Cyclin D1 protein expression and function in human breast cancer.
###end article-title 30
###begin article-title 31
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
###end article-title 31
###begin article-title 32
Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions.
###end article-title 32
###begin article-title 33
Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast.
###end article-title 33
###begin article-title 34
Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast.
###end article-title 34
###begin article-title 35
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
###end article-title 35
###begin article-title 36
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.
###end article-title 36
###begin article-title 37
Cyclin D1 provides a link between development and oncogenesis in the retina and breast.
###end article-title 37
###begin article-title 38
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice.
###end article-title 38
###begin article-title 39
Rescue of cyclin D1 deficiency by knockin cyclin E.
###end article-title 39
###begin article-title 40
###xml 37 41 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
###end article-title 40
###begin article-title 41
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 51 66 <span type="species:ncbi:10090">transgenic mice</span>
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
###end article-title 41
###begin article-title 42
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 16 20 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 34 38 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.
###end article-title 42
###begin article-title 43
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
###end article-title 43
###begin article-title 44
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
###end article-title 44
###begin article-title 45
###xml 95 98 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc</italic>
Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.
###end article-title 45
###begin article-title 46
Wnt and MEK1 cooperate to promote cyclin D1 accumulation and cellular transformation.
###end article-title 46
###begin article-title 47
beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression.
###end article-title 47
###begin article-title 48
Blocking oncogenic Ras signaling for cancer therapy.
###end article-title 48
###begin article-title 49
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">erb</italic>
Role of erb B2 in breast cancer chemosensitivity.
###end article-title 49

